The KRAS, BRAF, PIK3CA* Array simultaneously detects 20 point mutations within the KRAS, BRAF and PIK3CA genes. The assay is validated for use with DNA extracted from fresh/frozen and formalin fixed paraffin embedded (FFPE) tissue. Whilst the PIK3CA target is for research use only, the KRAS and BRAF targets are CE marked for routine clinical use.

Whilst designed for colorectal cancer, the KRAS, BRAF, PIK3CA* Array has implications for mutation screening in other cancer types, e.g. lung cancer.

The assay is based on a combination of multiplex PCR and biochip array hybridisation. Innovative PCR priming technology permits high discrimination between multiple targets. A unique primer set is designed for each target which will hybridise to a complementary oligo-nucleotide probe spotted on a biochip discrete test region (DTR). This combination of priming and spatially organised biochip array technology enables enhanced specificity of the assay. Analysis can be completed from template DNA through PCR to data readout in ~3 hours.

Points mutations detectable by the KRAS, BRAF,PIK3CA* Array


KRAS,BRAF,PIK3CA* Array protocol


Benefits of the KRAS, BRAF, PIK3CA* Array


Get in touch to discover more